Amiodarone versus lidocaine for shock-resistant ventricular fibrillation [3] (multiple letters)

New England Journal of Medicine

Volumn 347, Issue 5, 2002, Pages 368-370

  Silfvast, Tom ^a   Pettilä, Ville ^a   Ballew, Kenneth A ^a   Philbrick, John T ^a   Tomkiewicz, William ^a   Meininghaus, Dirk Grosse ^a   Langes, Klaus ^a   Spehn, Juergen ^a   Dorian, Paul ^a   Schwartz, Brian ^a   Cooper, Richard ^a  

^a HELSINKI UNIVERSITY CENTRAL HOSPITAL   (Finland)

Author keywords

[No Author keywords available]

Indexed keywords

AMIODARONE; LIDOCAINE; PLACEBO; ANTIARRHYTHMIC AGENT; EXCIPIENT; POLYSORBATE;

COST BENEFIT ANALYSIS; DRUG USE; HEART ARREST; HEART VENTRICLE FIBRILLATION; HOSPITALIZATION; HUMAN; LETTER; NEUROLOGIC DISEASE; PRIORITY JOURNAL; SURVIVAL; COMPARATIVE STUDY; MORTALITY; NOTE; SURVIVAL RATE; TIME; DOUBLE BLIND PROCEDURE;

AMIODARONE; ANTI-ARRHYTHMIA AGENTS; COST-BENEFIT ANALYSIS; HEART ARREST; HOSPITALIZATION; HUMANS; LIDOCAINE; SURVIVAL RATE; VENTRICULAR FIBRILLATION; TIME FACTORS; DOUBLE-BLIND METHOD; EXCIPIENTS; PLACEBOS; POLYSORBATES;

EID: 0036689162     PISSN: 00284793     EISSN: None     Source Type: Journal    
DOI: 10.1056/NEJM200208013470516     Document Type: Letter

References (0)